Quantum BioPharma Ltd. (QNTM) Announces Key Milestones; Price Target $12.80
Quantum BioPharma Ltd. (QNTM) Announces Key Milestones; Price Target $12.80
For more information on Quantum BioPharma, visit .LOS ANGELES, CA / ACCESSWIRE / August 30, 2024 / Quantum BioPharma Ltd. (QNTM) marks a significant milestone with the successful launch of unbuzzd on Amazon. This development coincides with the Company's rebranding and ticker change to QNTM. Additionally, recent ethics approval in Australia for a Phase-1 study of Lucid-MS represents a crucial advancement in the development of a novel treatment for Multiple Sclerosis.
加利福尼亞州洛杉磯/ACCESSWIRE/2024 年 8 月 30 日/Quantum BioPharma Ltd. (QNTM) 在亞馬遜成功推出unbuzzd，標誌着一個重要的里程碑。這一發展與公司的品牌重塑和股票代碼更改爲QnTM相吻合。此外，澳大利亞最近倫理批准了Lucid-MS的1期研究，這代表了多發性硬化症新療法開發的關鍵進展。
We maintain our Buy-Venture rating and have adjusted our target price to $12.80 per share, reflecting confidence in Quantum BioPharma's pioneering efforts in addressing brain disorders and alcohol health. The Company's strong pipeline includes Lucid-MS, targeting progressive Multiple Sclerosis, and unbuzzd, a formulation designed to expedite alcohol metabolism. With marketing experts Kevin Harrington and Gerry David leading unbuzzd's market launch, Quantum BioPharma is positioned for substantial growth.
我們維持買入風險投資評級，並將目標股價調整至每股12.80美元，這反映了對Quantum BioPharma在解決腦部疾病和酒精健康方面的開創性努力的信心。該公司強大的產品線包括針對進行性多發性硬化症的Lucid-MS和旨在加速酒精代謝的配方unbuzzd。在營銷專家凱文·哈靈頓和格里·戴維的領導下，Quantum BioPharma有望實現大幅增長。
For access to our research report on Quantum BioPharma, please click here.
要訪問我們關於量子生物製藥的研究報告，請點擊此處。
For more information on Quantum BioPharma, visit .
有關 Quantum BioPharma 的更多信息，請訪問。
For more information on Singular Research, visit .
有關奇異研究的更多信息，請訪問。
Singular Research
Research@SingularResearch.com
818-222-6234
單一研究
Research@SingularResearch.com
818-222-6234
SOURCE: Singular Research
來源：Singular Research
